Why the study?
Does ACE inhibitor therapy reduce all-cause hospitalization and total direct medical costs in patients with heart failure?
Does ACE inhibitor therapy reduce all-cause hospitalization and total direct medical costs in patients with heart failure?
In a managed care setting, ACE inhibitor therapy in heart failure patients is associated with significantly reduced risk of all-cause hospitalization and lower total direct medical costs.
May support ACE inhibitor use in heart failure to reduce hospitalizations and costs; leaves open need for randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Abarca et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: